Other substances

Imdevimab

An anti-Spike (SARS-CoV-2) antibody.

Phase of research

Emergency use authorization

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
9
 Clinical trials

General information

Imdevimab is a fully human monoclonal antibody targeting and neutralizing SARS-CoV-2 Spike protein (Hansen et al., 2020).

On November 21, 2020, FDA issued an emergency use authorization for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.

Synonyms

REGN10987

Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
antibody in vitro mixed substance peptide RNA small molecule Spike protein 		Caco-2 cells; Vero cells; Sera of vaccinated individuals; (VSV) SARS-CoV-2 Spike-pseudotyped virus (WT, B.1.1.7, B.1.351, ant P.1 variants) 38.64

Imdevimab displayed in vitro inhibition of SARS-CoV-2 Spike-pseudotyped virus infection for all tested emergent Spike variants (B.1.1.7, B.1.351, and P.1).

 Mar/20/2021 Apr/05/2021
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
antibody 		Vero E6 cells 41.85 2019

REGN10987+REGN10933 antibody cocktail

 Nov/23/2020 Nov/23/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04852978 COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers Recruiting Phase 2 Apr/29/2021 Aug/30/2022
NCT04790786 UPMC OPTIMISE-C19 Trial, a COVID-19 Study Recruiting Phase 3 Mar/10/2021 Dec/01/2022
NCT04666441 COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection Active, not recruiting Phase 2 Dec/15/2020 Aug/13/2021
NCT04840459 Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting Recruiting Phase 2 Nov/20/2020 Jan/31/2022
NCT04519437 Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 Active, not recruiting Phase 1 Jul/26/2020 Oct/25/2021
NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay Active, not recruiting Phase 3 Jul/13/2020 Sep/25/2021
NCT04425629 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 Recruiting Phase 2|Phase 3 Jun/16/2020 Nov/26/2021
NCT04426695 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 Active, not recruiting Phase 1|Phase 2 Jun/10/2020 Jun/04/2021
NCT04617535 Compassionate Use of REGN-COV2 for the Treatment of COVID-19 Available Jan/01/1970 Jan/01/1970
Excel (.xslx) CSV (.csv)